Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human antibody) versus trifluridine/tipiracil +/- bevacizumab plus placebo in metastatic colorectal cancer patients after failure of oxaliplatin, irinotecan, fluoropyrimidine

2024-517024-20-00 Protocol TASKIN Phase I and Phase II (Integrated) - Other Ongoing, recruitment ended

Start 27 Sep 2022 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 15 sites · Protocol TASKIN

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruitment ended
Participants planned 190
Countries 1
Sites 15

Metastatic colorectal cancer patients

Key facts

Sponsor
Centr Georges Francois Leclerc
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
27 Sep 2022 → ongoing
Decision date (initial)
2024-11-22
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517024-20-00
EudraCT number
2022-001400-18
ClinicalTrials.gov
NCT05201352

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic colorectal cancer patients

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centr Georges Francois Leclerc

Sponsor organisation
Centr Georges Francois Leclerc
Address
1 Rue Professeur Marion
City
Dijon
Postcode
21000
Country
France

Scientific contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Pr François GHIRINGHELLI

Public contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Emilie REDERSTORFF

Locations

1 EU/EEA country · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 190 15
Rest of world 0

Investigational sites

France

15 sites · Ongoing, recruitment ended
Institut Sainte Catherine
Oncology, 250 Chemin De Baigne Pieds, 84000, Avignon
Centre Hospitalier Regional Universitaire De Tours
Hepatogastroenterology and digestive oncology, 2 Boulevard Tonnelle, 37044, Tours Cedex 9
Institut Bergonie
Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
CHU Besancon
Oncology, 3 Boulevard Alexandre Fleming, 25000, Besancon
IHFB Cognacq Jay
Oncology, 4 Rue Kleber, 92300, Levallois-Perret
Institut De Cancerologie De L Ouest
Oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Centre Hospitalier Universitaire De Nantes
Oncology, 5 Allee De L Ile Gloriette, Cs 69301, Nantes Cedex 1
Centre Hospitalier Et Universitaire De Limoges
Oncology, 2 Avenue Martin Luther King, 87000, Limoges
Institut De Cancerologie De L Ouest
Oncology, 15 Rue Andre Boquel, 49100, Angers
CHU d'Estaing
Oncology, 1 place Lucie et Raymond Aubrac, 63100, Clermont-Ferrand
CARIO Centre Armoricain de Radiotherapie D'Imagerie medicale et D'Oncologie
Oncology, 10 Rue Francois Jacob, 22190, Plerin
Centre Hospitalier Universitaire De Poitiers
Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Centre Hospitalier Universitaire De Dijon
Oncology, 14 Rue Paul Gaffarel, 21000, Dijon
Institut Godinot
Oncology, 1 Rue Du General Koenig, 51100, Reims
Centr Georges Francois Leclerc
Oncology, 1 Rue Professeur Marion, 21000, Dijon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2022-09-27 2022-09-27 2025-06-27

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-11 France Acceptable
2024-11-22
2024-11-22
2 SUBSTANTIAL MODIFICATION SM-1 2025-03-21 France Acceptable
2025-05-16
2025-05-16